Background The use of antiplatelet agents is strongly recommended for the secondary
prevention of ischemic events such as myocardial infarction, stroke/transient ischemic attack …

Aims Antiplatelet therapy is recommended for the secondary prevention of cardio‐and
cerebrovascular disease, but for primary prevention it is advised only in patients at very high …

This case study reviews appropriate antiplatelet treatment options for an older patient post-
myocardial infarction and stent placement. This case investigates the benefits and risks …

Objective Despite the frequent use of antiplatelet medication (AM) in the elderly patients,
very few studies have investigated its prescription. We describe AM prescription through …

Older individuals (subjects aged> 65 years) largely contribute to the percentage deaths due
to myocardial infarction (MI) and stroke. The incidence of venous thromboembolism (VTE) is …

The long-term efficacy and side effects of antiplatelet and anticoagulant therapy for
secondary prevention after the first acute myocardial infarction (AMI) were retrospectively …

Antiplatelet drugs have been demonstrated to reduce the incidence of myocardial infarction
(MI), stroke or vascular death in patients with vascular disease. There are no data …

Antiplatelet drugs are a cornerstone for the management of all atherosclerosis-related
conditions, increasingly frequent with advanced age. Associations of antiplatelet drugs …

One-third to one-half of ischemic strokes occurred in patients taking antiplatelet drugs. The
optimal therapeutic strategy for antithrombotic drugs remains uncertain and guidelines …

With population ageing and rise of life expectancy, a progressively increasing proportion of
patients presenting with an acute coronary syndrome (ACS) are older adults, including those …